FOLD
Amicus Therapeutics Inc

6,359
Mkt Cap
$2.92B
Volume
2.75M
52W High
$10.36
52W Low
$5.51
PE Ratio
-212.08
FOLD Fundamentals
Price
$9.48
Prev Close
$9.38
Open
$9.25
50D MA
$8.45
Beta
0.84
Avg. Volume
5.13M
EPS (Annual)
-$0.1843
P/B
12.69
Rev/Employee
$1.06M
Loading...
Loading...
News
all
press releases
M&G PLC Takes Position in Amicus Therapeutics, Inc. $FOLD
M&G PLC bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Zacks·1d ago
News Placeholder
Profund Advisors LLC Boosts Stock Holdings in Amicus Therapeutics, Inc. $FOLD
Profund Advisors LLC grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 57.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·1d ago
News Placeholder
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Zacks·2d ago
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Grows Stake in Amicus Therapeutics, Inc. $FOLD
Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 133.9% in the second quarter, according to the company in its...
MarketBeat·3d ago
News Placeholder
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Zacks·4d ago
News Placeholder
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned an average rating of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat.com reports...
MarketBeat·4d ago
News Placeholder
Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·5d ago
News Placeholder
Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets
EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets been highlighted in this Screen of The Week article.
Zacks·5d ago
News Placeholder
Amicus Therapeutics (NASDAQ:FOLD) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.12...
MarketBeat·8d ago

Latest FOLD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.